Blog

Editorial Note: This is the fourth of four posts about the links between Sense about Science and AllTrials. The first was Follow the Rhetoric. The Second was First Admit no Harm. The third was Follow the Lawsuit. The simple act of defining doctors or patients concerned about adverse events as “critics” is a rhetorical stroke that marginalizes concerns - makes you a one … [Read more...] about Sense about Science: Follow the Patient

Editorial Note: This is a third in a series of posts about Sense about Science and Access to Clinical Trial Data that began with Follow the Rhetoric and followed up with First Admit no Harm. There are some facts in the last few posts. There are also some extrapolations that may not be right. Tracey Brown has gone on the Parliamentary Record to make clear what AllTrials are … [Read more...] about Sense about Science: Follow the Lawsuit

Editorial Note: This is a second post exploring Sense about Science. The first post Follow the Rhetoric is here. Anyone interested in Pharma will know about its ability to Astroturf – to create patient organizations whose role is to promote an illness or subvert an existing one. Creating awareness of conditions sells drugs. On a higher astral plane Less well known is what … [Read more...] about Sense about Science: First Admit No Harm

Editorial Note: This is the first of four posts about the link between Sense about Science and AllTrials triggered by the post Fucked and comments afterward by Ben Goldacre, Tracey Brown and others which raised these links. My first contact with Sense about Science was linked to the Simon Singh affair. Singh had made some relatively innocuous statements about chiropractic and … [Read more...] about Sense about Science: Follow the Rhetoric

(First published in the PLOS Blog. Click here for the original post.) Things were looking good recently in Europe for data transparency, a necessary, albeit not sufficient, tool to promote integrity of pharmaceutical data. The European Court’s Vice-President overturned in November 2013 two lower court interim suspensions of EMA’s data access decision in relation to Abbvie’s … [Read more...] about Trudo Lemmens of the University of Toronto critiques the recently distributed draft EMA Clinical Trials Data Release Policy

Editorial Note: Motivational interviewing began as a technique to help opiate or nicotine addicts or alcoholics. The idea was to move them through contemplation of the possibility of change, to having an action plan and then acting. It recognized that there was no point just arguing that addiction was wrong - you had to understand a person as well as they understood themselves … [Read more...] about Motivational Interviewing